MONOCLONAL ANTIBODIES DEFINE CARCINOMA ASSOCIATED AND DIFFERENTIATION ANTIGENS

这些研究涉及到细菌的产生、表征和利用。 针对相关抗原的单抗(MAb) 人类的癌症。这些单抗被用来更好地理解 几种人类癌症的细胞生物学和发病机制并提供 在人类管理的几个领域中可能有用的试剂 癌症。这包括通过血清检测和/或体外诊断 免疫组织病理学，活体诊断，如伽马扫描，以及 潜在的治疗方法。产生的单抗可以分为两类 基于检测到的抗原的表达的分组。这些是(A)项 人类肿瘤与正常成人差异表达的抗原 组织，如肿瘤相关糖蛋白(TAG)-72 其由单抗B72.3和CC49检测，以及癌胚抗原 (CEA)由单抗Col-1至Col-15检测到的；或(B) 组织相关抗原，如检测到的结肠相关抗原 单抗D612。 由于已经证明单抗B72.3选择性地针对一系列 癌症的临床试验涉及1000多名患者，研究是 对一系列“第二代”单抗进行了表征 TAG-72抗原。这些研究表明，其中一些第二种 CC83和CC49等世代CC单抗具有更高的亲和力 TAG-72的常量比B72.3更适合，可能比B72.3更适合 一些临床应用。 260例结直肠癌患者血清中TAG-72的检测 疾病(恶性或良性)已使用CA72-4检测进行评估。 大约40%的结直肠癌患者表现为升高 这一标志物的水平，而且，阳性水平的存在 TAG-72与疾病的晚期显著相关。这些 研究表明，同时使用TAG-72和CEA血清标志物 可能对复发性疾病的诊断有用，因此 在癌症患者的临床管理中发挥作用。

These studies involve the generation, characterization, and utilization of monoclonal antibodies (MAbs) directed against antigens associated with human carcinomas. These MAbs are being used to better understand the cell biology and pathogenesis of several human carcinomas and to provide reagents that may be useful in several areas of the management of human carcinoma. These include in vitro diagnosis via serum assays and/or immunohistopathology, in vivo diagnosis such as gamma scanning, and potentially therapy. The MAbs generated can be classified into two groups based on the expression of the detected antigens. These are (a) antigens differentially expressed in human carcinoma versus normal adult tissues, such as the pancarcinoma tumor-associated glycoprotein (TAG)-72 which is detected by MAbs B72.3 and CC49, and carcinoembryonic antigen (CEA) which is detected by MAbs COL-1 through COL-1 5; or (b) tissue-associated antigens, such as the colon-associated antigen detected by MAb D612. Since MAb B72.3 has been shown to selectively target a range of carcinomas in clinical trials involving over 1000 patients, studies were conducted to characterize a series of 'second generation' MAbs to the TAG-72 antigen. These studies demonstrated that some of these second generation CC MAbs, such as CC83 and CC49, have a higher affinity constant for TAG-72 than B72.3, and may be better suited than B72.3 for some clinical applications. The presence of TAG-72 in serum samples from 260 patients with colorectal disease (malignant or benign) has been evaluated using the CA72-4 assay. Approximately 40% of patients with colorectal cancer exhibit elevated levels of this marker, moreover, the presence of positive levels of TAG-72 significantly correlates with advanced stages of disease. These studies suggest that the simultaneous use of TAG-72 and CEA serum markers may be useful in the diagnosis of recurrent disease and may therefore play a role in the clinical management of cancer patients.